



Press release 2014-11-26

C-RAD concludes sales agreement with Elekta K.K. for Japanese market

C-RAD and Elekta K.K. signed an agreement for sales and service of Catalyst™ and Sentinel™ in Japan. Both products have received approval from the Japanese authorities.

With the approvals for Sentinel 4DCT and Catalyst, C-RAD and its partner are allowed to quote, sell and install these systems in Japan. C-RAD and Elekta K.K. started the product approval process in 2013. In November the Japanese authorities issued the required license. The Japanese market is the second largest radiotherapy market worldwide, with close to 800 treatment centers.

The agreement gives Elekta K.K. the distribution rights to package and sell the systems together with new linear accelerators, and also to upgrade existing customers.

Japan's major radiotherapy convention – JASTRO – will take place in December in Yokohama. C-RAD will be present for the first time to provide live demonstrations of the Catalyst System to customers.

The Catalyst and Sentinel systems offer the technology required to perform highly advanced treatment methods within radiation therapy. With these solutions C-RAD supports the whole 4D treatment chain from imaging to delivery. Respiratory-gated treatments are frequently used when the target volume is close to cardiac tissue or for special treatments in which the tumor position depends on the respiratory cycle.

Shuichi Higaki, President, Elekta K.K. says: “By including Sentinel 4DCT and Catalyst to our portfolio, we’ll be able to offer customers improved patient positioning, resulting in an enhanced clinical workflow.”

“We are delighted to begin this marketing cooperation and to exploit the significant potential of the Japanese market,” says Tim Thurn, CEO of C-RAD. “The cooperation gives C-RAD and Elekta the opportunity to provide the market-leading gating solution, as well as our solutions for patient positioning and motion monitoring, to our customers in Japan. We are looking forward to a prosperous cooperation with our partner.”

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 28. C-RAD's business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD holds 29% of the laser company Cyrpa with an option to acquire the remaining 71%. C-RAD AB is listed since March 2010 on NASDAQ OMX First North Premier. Erik Penser Bankaktiebolag is appointed as C-RAD's Certified Adviser.

For more information on C-RAD, please visit www.c-rad.com.



For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, E-mail investors@c-rad.com

The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2077:528).